BR9813114A - Use of TNF antagonists to produce medicines, commercial package, and process to establish whether a patient suffering from sepsis should be treated with TNF antagonists - Google Patents

Use of TNF antagonists to produce medicines, commercial package, and process to establish whether a patient suffering from sepsis should be treated with TNF antagonists

Info

Publication number
BR9813114A
BR9813114A BR9813114-1A BR9813114A BR9813114A BR 9813114 A BR9813114 A BR 9813114A BR 9813114 A BR9813114 A BR 9813114A BR 9813114 A BR9813114 A BR 9813114A
Authority
BR
Brazil
Prior art keywords
tnf antagonists
sepsis
treated
commercial package
patient suffering
Prior art date
Application number
BR9813114-1A
Other languages
Portuguese (pt)
Inventor
Hartmut Kupper
Martin Kaul
Juergen Eiselstein
Lothar Daum
Joachim Kempeni
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of BR9813114A publication Critical patent/BR9813114A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE ANTAGONISTAS TNF PARA PRODUZIR MEDICAMENTOS, PACOTE COMERCIAL, E, PROCESSO PARA ESTABELECER SE UM PACIENTE QUE ESTEJA SOFRENDO DE SéPSIS DEVA SER TRATADO COM OS ANTAGONISTAS TNF". A invenção se relaciona com a aplicação de antagonistas TNF para produzir medicamentos para o tratamento de doenças sépticas caracterizadas por um bruto crescente do nível de interleucina-6 no soro durante um intervalo de medição de no mínimo trinta minutos."USE OF TNF ANTAGONISTS TO PRODUCE MEDICINES, COMMERCIAL PACKAGE, AND, PROCESS TO ESTABLISH IF A PATIENT WHO IS SUFFERING WITH SEPSIS SHOULD BE TREATED WITH TNF ANTAGONISTS". The invention relates to the application of TNF antagonists to produce drugs for the treatment of septic diseases characterized by an increasing crude level of interleukin-6 in the serum during a measurement interval of at least thirty minutes.

BR9813114-1A 1997-10-23 1998-10-15 Use of TNF antagonists to produce medicines, commercial package, and process to establish whether a patient suffering from sepsis should be treated with TNF antagonists BR9813114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19746868A DE19746868A1 (en) 1997-10-23 1997-10-23 Use of tumour necrosis factor antagonists
PCT/EP1998/006545 WO1999021582A2 (en) 1997-10-23 1998-10-15 Application of tnf antagonists as medicaments for treating septic diseases

Publications (1)

Publication Number Publication Date
BR9813114A true BR9813114A (en) 2000-08-15

Family

ID=7846420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813114-1A BR9813114A (en) 1997-10-23 1998-10-15 Use of TNF antagonists to produce medicines, commercial package, and process to establish whether a patient suffering from sepsis should be treated with TNF antagonists

Country Status (13)

Country Link
EP (1) EP1024831A2 (en)
JP (1) JP2001521009A (en)
KR (1) KR20010024549A (en)
CN (1) CN1163272C (en)
AU (1) AU756167B2 (en)
BR (1) BR9813114A (en)
CA (1) CA2306790A1 (en)
DE (1) DE19746868A1 (en)
HU (1) HUP0100105A3 (en)
IL (1) IL135083A0 (en)
NO (1) NO20001894L (en)
WO (1) WO1999021582A2 (en)
ZA (1) ZA989615B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (en) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Method of treatment of pathological syndrome and medicinal agent
UA76639C2 (en) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Homeopathic medication and method for treating erectile dysfunctions
UA76640C2 (en) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Method for correcting pathological immune responses and homeopathic medicinal agent
RU2309732C1 (en) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Pressed solid oral formulation of medicinal preparation and method for preparing solid oral formulation of medicinal preparation
SG187035A1 (en) 2010-07-15 2013-02-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
FR2962656A1 (en) 2010-07-15 2012-01-20 Oleg Iliich Epshtein METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY
EP2415461B1 (en) * 2010-07-24 2012-10-31 Roche Diagnostics GmbH Stabilization of interleukin 6 in serum based solutions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626572B2 (en) * 1988-07-18 1992-08-06 Chiron Corporation Monoclonal antibodies reactive with cachectin
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
CA2306790A1 (en) 1999-05-06
CN1277556A (en) 2000-12-20
IL135083A0 (en) 2001-05-20
AU1228499A (en) 1999-05-17
EP1024831A2 (en) 2000-08-09
AU756167B2 (en) 2003-01-09
NO20001894D0 (en) 2000-04-12
JP2001521009A (en) 2001-11-06
DE19746868A1 (en) 1999-04-29
WO1999021582A3 (en) 1999-07-15
CN1163272C (en) 2004-08-25
KR20010024549A (en) 2001-03-26
WO1999021582A2 (en) 1999-05-06
NO20001894L (en) 2000-04-12
HUP0100105A3 (en) 2003-08-28
HUP0100105A2 (en) 2001-05-28
ZA989615B (en) 2000-04-20

Similar Documents

Publication Publication Date Title
ATE207356T1 (en) USE OF TIAGABINE TO TREAT SLEEP DISORDERS
DE69738000D1 (en) New pharmaceutical formulation containing budesonide
IT1269826B (en) USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS
BR9706835A (en) Implantable acrylamide copolymer hydrogel for therapeutic uses
ATE135231T1 (en) USE OF ''CARTILAGE-INDUCING FACTOR'' (CIF) TO TREAT HEMATO- OR LYMPHOPOIETIC DISEASES
DE69325998D1 (en) USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE ACID FOR PROMOTING NITROGEN RETENTION IN PEOPLE
DE69034018T2 (en) COMBINED USE OF HYALURONIC ACID AND THERAPEUTIC ACTIVE SUBSTANCES TO IMPROVE THE THERAPEUTIC EFFECT
ATE310501T1 (en) ADMINISTRATION OF NEUROTROPIC AGENTS INTO THE CENTRAL NERVOUS SYSTEM
PT998288E (en) COMPOSITIONS CONTAINING CAPSAICIN OR ANALOGUES OF CAPSAICIN AND A LOCAL ANESTHETIC
ATE256463T1 (en) PHARMACEUTICAL PREPARATION FOR USE IN THE TREATMENT OF DIABETES
DE60113815D1 (en) TREATMENT OF CYTOKIN-MEDIATED DISEASES WITH TEC FAMILY PROTEIN TYROSINE KINASE INHIBITORS
DE3650647D1 (en) Medicines used to treat anxiety
BR9813114A (en) Use of TNF antagonists to produce medicines, commercial package, and process to establish whether a patient suffering from sepsis should be treated with TNF antagonists
DE69711078D1 (en) TOPICAL USE OF KAPPA OPIOID RECEPTORAGONISTS FOR THE TREATMENT OF EYE PAIN
ATE338575T1 (en) USE OF FLUMAZENIL IN THE DEVELOPMENT OF A DRUG FOR THE TREATMENT OF ALCOHOL DEPENDENCE
PE11399A1 (en) COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA
ATE119770T1 (en) USE OF ACETYL L-CARNITINE FOR THE THERAPEUTIC TREATMENT OF COMA.
DE69821498D1 (en) USE OF AMIFOSTIN
ATE210447T1 (en) USE OF CCK-B RECEPTOR ANTAGONISTS TO TREAT SLEEP DISORDERS
BR9809673A (en) Triptolide derivatives useful in the treatment of autoimmune diseases
PT1007093E (en) METHODS FOR THE TREATMENT OF DISORDERS THROUGH THE USE OF INTERLEUCIN-9 AND ITS ANTAGONISTS
ATE67410T1 (en) METHOD OF TREATMENT OF ANTIDIURESIS.
BR0012006A (en) Method to prevent inflammation, autoimmune diseases and tumor growth, and use of substances that suppress ltbr-mediated activation
NO984197D0 (en) Procedures for treating autism
DE69720064D1 (en) USE OF COMT INHIBITORS FOR PRODUCING A MEDICINAL PRODUCT FOR PREVENTING DIABETIC VASCULAR FUNCTIONAL DISORDERS

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25A Requested transfer of rights approved

Free format text: ABBOTT GMBH (DE)

B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.